| Objective To investigate the effect of Resveratrol on protein biomarkers of postmenopausal women with osteoporosis. Methods Eighty-four postmenopausal osteoporosis patients treated in our hospital from November 2015 to November 2017 were selected as the study subjects; all patients were randomly divided into two groups: the resveratrol treatment group and the control group. The treatment group participants took resveratrol daily for 3 month and the control group participants took placebo tablets in the same way. After 3 months, serum bone metabolism markers type I procollagen amino terminal propeptide (PINP), osteocalcin (BGP), bone alkaline phosphatase (BALP), type I collagen C-terminal peptide specific sequence (β-CTX), plasma protein carbonyl (PCO), advanced oxidation protein product (AOPP), total antioxidant capacity (TAC), and Akatsu (MDA) levels were measured. Results After treatment with resveratrol, serum PINP, BGP, BALP,β-CTX , PCO, AOPP and MDA levels of this group were significantly lower than before treatment (P<0.05), and there was also a statistically significant difference between the two groups after treatment (P<0.05); resveratrol group Serum TAC levels were significantly higher than before treatment (P<0.05); in addition, there was a significant statistical difference between the two groups after treatment (P<0.05); however, No difference of the above indicators PINP, BGP, BALP,β-CTX PCO, TAC, AOPP and MDA were observed before and after treatment in the control group (P>0.05). Conclusion Resveratrol can reduce oxidative stress and high bone turnover rate in postmenopausal women with osteoporosis. |